Maia Biotechnology, Inc. · AMEX:MAIA
Maia Biotechnology — Investor Presentation (May 2024)
32 slides from Maia Biotechnology's investor presentation, May 7, 2024
Slide 1: MAIA Biotechnology: Telomere Targeting Immunotherapies for Cancer
MAIA BIOTECHNOLOGY TELOMERE TARGETING IMMUNOTHERAPIES FOR CANCER NYSE AMERICAN: MAIA May 2024
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS NYSE American: MAIA, All statements inthis presentation, other than those relating to historical facts, are forward-looking statements." These forward-looking statements may include, but are not limited to, statements relating to our objectives, plans, and strategies; stat
Slide 3: Company Profile
ENT PROFILE New science for cancer therapy: dual MOA telomere targeting and immunogenicity. * Lead molecule THIO in clinic; 2nd generation compounds in R&D Phase 2 trial THIO-101 nearing completion: THIO sequenced with CPI in NSCLC. + Unprecedented disease control, response, post-therapy patient ben
Slide 4: Robust Pipeline
ROBUST PIPELIN PHASE 1 | PHASE 2 |PHASE3/ COLLABORATION & THIO Telomere targeting agent RIGHTS THIO-104 NSCLC-2+ (THIO — Libtayo®) eo eta spond by Mata” REGENERON THIO-102 CRC, HCC, SCLC, ST (THIO = CPI) prerring po THIO-103 NSCLC-1, SCLC-1 (THIO cP) [ {n2?. area oer 2"4 Generation Telomere targetin
Slide 5: Mission and Approach
NYSE American: MAIA, MISSION AND APPROACH
Slide 6: Cancer and aging population statistics
Population aged >80 I ’ \ {i ——_ expected to triple by 2050 fe) Cancer is the 142 At age 90 i =e age 90: | eeeecrelated | million 40% will be diagnosed ay | Fi 20% will die of it disease
Slide 7: THIO is the only direct telomere targeting anticancer agent in clinical development
PY THIO is the only direct telomere targeting anticancer agent in clinical development
Slide 8: THIO dual mechanism of action
THIO THIO has a dual MoA: Z DmMANZ . + 5 i @ Telomere targeting Jena PUBTAYO |S cuvatumat @® Immunogenic effect REGENERON || Astazenecd KEYTRUDA || re¥onoea PD-L1, P (pembrolizumab) (tislelizumab) © merck BeiGene AntPO = Followed by cr ae 4 cy , TECENTRIG’ > * (atezolizumab) ner Fz x Saget orpwo | @
Slide 9: THIO-101 NSCLC Trials - Rationale
THIO-101 NSCLC TRIALS - RATIONALE Cycle 1 Cycle 2 * THIO followed by CPI results in 60% 1000 ae complete response 900 —*-Atezolizumab * Only 2 cycles of therapy were 800 =e THIO administered on weeks 1 and 2; no No cancer further therapy throughout the study 00 TT THIO > Atezo immune memory * No rec
Slide 10: THIO-101 Trial: Non-Small Cell Lung Cancer
NYSE American: MAIA, THIO-101 TRIAL NON-SMALL CELL LUNG CANCER
Slide 11: Regeneron Agreement
REGENERON AGREEMENT MAIA & REGENERON BIOTECHNOLOGY ____ MAIA Biotechnology, Inc. Announces Clinical Supply Agreement with | Regeneron for Phase 1/2 Clinical Trial Evaluating THIO in Sequential Administration with Libtayo® (cemiplimab) in Advanced Non-Small Cell Lung Cancer aa
Slide 12: Design
DESIGN A Multicenter, Open-Label, Dose-Finding Phase 2 Trial Evaluating the Safety and Efficacy of THIO Administered in Sequence with LIBTAYO® (cemiplimab) in NSCLC patients RESISTANT TO CHECKPOINT INHIBITORS Part A: Expansion: _ Safety Registration? Every 3 Weeks w cl. | |N o se NSCLC-3 2sS| |S < 2
Slide 13: Patients' Survival by Line of Therapy
PATIENTS' SURVIVAL BY LINE OF THERAPY (ala NYSE American: MAIA, Third Line+ (All Doses): 24 patients ine (All Doses): 44 patients Median Survival Follow-Up? 7.0 months realment > Ongoing SS Fotowlp > Onasng % Stabe see (6) B Pata Response PR) 1A Proressive Deas PO) death 8 ncaa PFS] 8 ohne o 12 89 4
Slide 14: Treatment in Third-Line
TREATMENT IN THIRD-LINE Third Line (All Doses): 20 patients Extended Survival — , * 20 subjects in 3L completed at least 1 post baseline assessment at time of cut-off * 13/20 (65%) patients crossed 5.8 months OS threshold * 17/20 (85%) crossed 2.5 months PFS threshold Unprecedented Efficacy + DCR 85
Slide 15: Best 3L Results in the 180mg Dose
BEST 3L RESULTS IN THE 180MG DOSE NSCLC-3 - 180mg: Third Eine (180mg) * 6/8 (75%) patients crossed 5.8 ooo months OS threshold oo of ofa + 7/8 (88%) crossed 2.5 months PFS j threshold ne = > Median Survival Follow-Up? 8.9 months Months Note: This is snapshot including ongoing subjects and data pendi
Slide 16: Expected Efficacy vs Current Treatment
EXPECTED EFFIC. CURRENT TREATMENT THIO (180mg) + emothars mab) Py (docetaxel) Population CPI Resistant (3L) CPI Naive (3L) CPI Naive (2L+) CPI Naive (2L) DCR 88% 36% 45% 5A% ORR 38% 6% 9% 5.7% 1.9 months PFS e eit 2.2 months (8.3 weeks Time to Pro} Progression) os pale montis 5.8 months 6.7 months 5
Slide 17: Planned Upcoming Trials
NYSE American: MAIA, PLANNED UPCOMING TRIALS
Slide 18: THIO-102 Trial (Planned)
THIO-102 TRIAL (PLANNED) A Multicenter, Open-label, Phase 2 Trial Evaluating the Safety and Efficacy of THIO Administered in Sequence with Anti-PD-1 or Anti-PD-L1 Part A/B: Safety/Efficacy Signal Part C: Pivotal Phase 2 Baskets Umbrella Arms Colorectal Cancer (CRC) Hepatocellular Carcinoma (HCC) THI
Slide 19: THIO-102 Colorectal Rationale
THIO-102 — COLORECTAL RATIONALE . 700 + THIO followed by CPI results in 100% 600 er Control complete response = ~e-Atezolizumad € 500 —e-THIO * Only 2 cycles of therapy were 2 400 administered on weeks 1 and 2; no 2 300 —e—THIO ~ Atezo further therapy throughout the study ra g 200 100% CR +» No recu
Slide 20: SCLC & HCC - Orphan Drug Designation
SCLC & HCC - ORPHAN DRUG DESIGNATION (ala SCLC Control —e—Pembro > THIO —e—THIO > Pembro Tumor Volume (mm?) ~ a 3 0 5 10 15 20 25 Days After Tumor Inoculation THIO is synergistic with anti-PD-1 agent Pembrolizumab in Small Cell Lung Carcinoma (H20841) in vivo in humanized murine cancer model Treatme
Slide 21: Excellent Efficacy in HCC Models
EXCELLENT EFFICACY IN HCC MODELS S 6007|-<- Control + THIO achieved complete and durable responses in E Hepatocellular Carcinoma (HCC), the dominant ~ 400 histology in primary liver cancer (90%), in in vivo 2 models 2 ) 2 200 2 100% CR = 1 E 0 0 5 101520 2530354045 Days after tumor inoculation 2a
Slide 22: HCC Anti-Cancer Immune Memory
HCC ANTI-CANCER IMMUNE MEMORY * When combined with immunotherapy checkpoint inhibitor Libtayo®, duration of response was further potentiated + Upon rechallenge with two times more cancer cells and no additional treatment, tumor growth was completely prevented + Administration of THIO alone and in co
Slide 23: THIO-103 Trial (Planned)
THIO-103 TRIAL (PLANNED) A Multicenter, Open-label, Phase 2 Trial Evaluating the Safety and Efficacy of THIO Administered in Sequence with Anti-PD-1 or Anti-PD-L1 Part A/B: Safety/Efficacy Signal Part C: Pivotal Phase 3 Baskets SCLCFirstLine iMesh toys EP + TECENTRIQ (atezolizumab) Expand to Pivotal
Slide 24: Investment Opportunity
NYSE American: MAIA, INVESTMENT OPPORTUNITY
Slide 25: Exclusivity and Intellectual Property
EXCLUSIVITY AND INTELLECTUAL PROPERTY =] Goal: New Chemical Entity (NCE) Marketing Exclusivity NA * THIO has never been previously approved by the FDA for commercialization * Robust exclusivity ¢ US: 7 years; EU, Japan, other markets: 10 years Robust and Growing Patent Portfolio for THIO + 5 issued
Slide 26: Experienced Management Team
EXPERIENCED MANAGEMENT TEAM <4 Vlad Vitoc, MD, MBA Sergei Gryaznov,PhD Jeffrey Himmelreich, MBA Founder and CEO Chief Scientific Officer Head of Finance + 24+ years in Oncology Pharma/ + 25+ years as Scientist * 20+ years of financial Biotech: Commercial, Medical + Expert Drug Discovery and expertis
Slide 27: Significant Market Opportunity
IGNIFICANT MARKET OPPORTUNITY Developing agents for the top tumor types markets globally NSCLC (#1 Ww) HCC Mortality: 1.7M / Sales: $34B | Mortality: 0.8M / Sales: $3B CRC (#2 WW) SCLC Mortality: 1.0M / Sales: $20B Mortality: 0.3M / Sales: $2B 5 CPIs approved for NSCLC: * > 30% of NSCLC drug sales +
Slide 28: Peer comparison and market caps
oe —— aT) & (yi) M AIA iM | RATI.” «zontal 9 TOVANCE; @KURA A leon roe BIOTECHNOLOGY M THERAPEUTICS plorWERAPEUTICS wee $4.1B ‘$0.88 $3.2B $1.4B $4.1B Market Cap Market Cap Market Cap Market Cap Market Cap Market Cap $2.69/share $58/share $11/share $12/share $19/share $76/share * On June 3, 2022, Br
Slide 29: Multiple Value-Driving Milestones
MULTIPLE VALUE-DRIVING MILESTONES o& Major inflection points 2024 2025 2026 THIO-101 Early PartB PartB PartB Part C Part C Filing for Potential Ph2 Efficacy Efficacy Long-term Full Efficacy Enrollment us Accelerated NSCLC-2+ Update (ASCO) Efficacy Efficacy Update Complete approval Approval in (Biote
Slide 30: Thank You
THANK YOU Investor Relations Contact +1 (872) 270-3518 ir@maiabiotech.com MAIA Biotechnology, Inc. 444 West Lake Street, Suite 1700 Chicago, IL 60606 NYSE American: MAIA, 30
Slide 31: Appendix
NYSE American: MAIA, APPENDIX
Slide 32: U.S. FDA Granted Orphan Drug Designations to THIO
U.S. FDA GRANTED 3 ORPHAN DRUG DESIGNATIONS TO THIO (w™ (6) MAIA * The FDA’s Orphan Drug Act of 1983 is designed to incentivize the FDA, development of therapies that demonstrate promise for the treatment 3 > rl of rare (orphan) diseases or conditions re + Rare disease - affects fewer than 200,000 p
MAIA Biotechnology — Investor Presentation (May 2024) on 6ix